English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Fosun Pharma and Dalian Wanchun Announce Partnership

Dec. 10, 2012

Shanghai Fosun Pharma and Dalian Wanchun Biotech will establish a joint venture to develop innovative oncology treatments. Wanchun has in-licensed China rights to plinabulin, a Class 1.1 innovative anti-tumor drug from Nereus Pharma of the US. Through the JV, Fosun will build Wanchun’s development capability and add potential drugs to its pipeline. Wanchun will serve as an innovative drug incubator for Fosun.